: Vaginal Atrophy. Diseases of the genitourinary system (N00-N99)
Conditions
Interventions
Intervention 1: Group 1, will be received an intervention that included vaginal suppositories vitamin D (1000 IU Vitamin D in addition to 2 gr the base material), once a day for 2 months. Intervention
Treatment - Drugs
Group 1, will be received an intervention that included vaginal suppositories vitamin D (1000 IU Vitamin D in addition to 2 gr the base material), once a day for 2 months
Group 2, will be received an intervention that included vaginal suppositories vitamin E, (1 mg vitamin E in addition to 2 gr the base material), once a day for 2 months
Control group, the women in control group will be received placebo vaginal suppositories containing 2 gr base material, (Suppocire AS2), once a day for 2 months
Sponsors
Vice chancellor for research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
17 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: being married; having stage 1 and 2 breast cancer based on surgery staging; use of tamoxifen; non-use of chemotherapy or radiation during this study; aged under 50 years; with at least one of the symptoms of the self-assessment urogenital atrophy questionnaire; normal Pap smear within the last 3 years; no proven cancer in other organs of the body based on the results recorded in patient records; having sexual activity.Exclusion criteria: vaginal infection (confirmed by Microbiological analysis); abnormal Pap smear; estrogen therapy during the past 8 weeks; unexplained vaginal bleeding; recurrent disease based on the diagnostic results recorded in patient records; smoking cigarette.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaginal ph. Timepoint: Before intervention, Two weeks after the intervention, Four weeks after intervention, eight weeks after intervention. Method of measurement: PH indicator strip. | — |
Secondary
| Measure | Time frame |
|---|---|
| Vaginal cell Maturation. Timepoint: Before intervention, eight weeks after intervention. Method of measurement: Vaginal Maturation Index.;Symptoms of vaginal atrophy. Timepoint: Before intervention, Two weeks after the intervention, Four weeks after intervention, eight weeks after intervention. Method of measurement: Self-assessment urogenital atrophy questionnaire (UAQ). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Roksana Janghorban
School of Nursing and Midwifery, Shiraz University of Medical Sciences
Outcome results
None listed